A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

News

News

All the latest news about the Access to Medicine Foundation, our research programmes and engagement activities. 

All Access to Medicine Foundation Access to Medicine Index Antimicrobial Resistance Benchmark Access to Vaccines Index

09 Jun 2022

Drug makers must address access to antibiotics to help slow the superbug threat

New report sets out six case studies of drug makers that are increasing local access to antibiotics and antifungals, including through technology tran...

25 May 2022

Look ahead: what will the 2022 Access to Medicine Index uncover?

Due for release in November, the next Index will include three special reports. Each one will join the dots between long-standing global health priori...

12 May 2022

Generics companies are exploring new ways to increase access to medicine

Generic medicine manufacturers play a vital role in making essential health products available and accessible. But in a changing global health la...

01 Mar 2022

Three ways to fix healthcare supply chains and improve global health security

The global supply of essential medicines and vaccines is currently highly vulnerable to disruption. To address this urgent problem, the Access to Medi...

24 Feb 2022

As the pandemic passes, has progress been made on access to medical oxygen?

As the world moves forward from the pandemic, an integrated solution is still needed to address chronic problems with medical oxygen supply that preda...

10 Jan 2022

Foundation to deepen its work moving pharma companies on access to diabetes care

Each year, more than 100,000 children and young adults are diagnosed with type 1 diabetes. Although the products that can keep them alive do exist, th...

14 Dec 2021

Taking access to the next level: mobilising five essential healthcare sectors

With a new strategic direction for 2022-2026, the Access to Medicine Foundation will be expanding the range of companies and healthcare sectors which...

03 Dec 2021

Jane Masiga and Patrick Flochel bring breadth of experience as new Supervisory Board members

Jane Masiga and Patrick Flochel have joined the Supervisory Board of the Access to Medicine Foundation, in two significant appointments that will help...

18 Nov 2021

Signs of progress by pharma against superbugs, yet little movement to address access

Pharma companies press on in fight against superbugs despite COVID-19 pandemic, finds the 2021 Antimicrobial Resistance Benchmark. But action to impro...

02 Nov 2021

What are pharma companies doing to slow the superbugs? New report out soon.

Superbugs threaten to cause the next pandemic. On Thursday 18 November, the Access to Medicine Foundation will publish the 2021 Antimicrobial Res...

22 Sep 2021

New Index methodology: capacity to track progress prioritised for 2022

The Methodology Report for the next Access to Medicine Index is now online. It sets out the metrics the Access to Medicine Foundation will use in 2022...

13 Jul 2021

7 lessons from COVID-19 for pharma companies

There is a long way to go to curb the COVID-19 pandemic. To speed the end of the pandemic, and support a recovery that leaves no-one behind, the Acces...

22 Jun 2021

Foundation names Expert Review Committee for 2022 Access to Medicine Index

The Access to Medicine Foundation is pleased to announce the members of the Expert Review Committee for the next Access to Medicine Index, including f...

16 Jun 2021

Global oxygen suppliers commit to closing oxygen gaps in low- and middle-income countries

Two of the world’s largest medical oxygen suppliers have agreed to work with the COVID-19 Oxygen Emergency Taskforce to increase access to medical oxy...

10 Jun 2021

Biotech’s antibiotic warriors need new reward system in superbug fight

Today, a new report by the Foundation examines how small drugmakers, which are pivotal in antibiotic development, are navigating the to...

25 Mar 2021

Handful of new children’s meds on the horizon. But will they be accessible to children in LMICs?

New analysis: Just 7% of pharmaceutical companies’ R&D is for children under 12, despite significant gaps in paediatric treatment options.

Back to top |